According to the study by Next Move Strategy Consulting, the growth drivers for the Lumakras Market include its pioneering role as the first FDA-approved KRAS G12C inhibitor for treating non-small cell lung cancer (NSCLC), addressing a previously untreatable genetic mutation. The increasing incidence of NSCLC and the rising demand for targeted therapies are key factors propelling its market expansion.